<DOC>
	<DOC>NCT00822341</DOC>
	<brief_summary>TG-0054 is a CXCR4 antagonist with stem cell mobilization effect as proven in animal model, this is the fist in human study to investigator the safety, tolerability and PK/PD in healthy subjects.</brief_summary>
	<brief_title>Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male or female 18 to 45 years of age inclusive Body mass index (BMI) in the range of 19.0 to 30.0 kg/m² and body weight ≥ 50 kg inclusive Good physical and mental health status determined on the basis of the medical history and a general clinical examination Subjects must have used a consistent form of acceptable oral birth control or the double barrier method (intrauterine device (IUD) plus condom, spermicidal gel plus condom) for at least 3 months prior to study initiation Any medical condition (other than a selflimited illness) that requires ongoing and current medical attention History of any other hematologic disorders including thromboembolic disease or anemia Severe trauma, fracture, major surgery, or biopsy of a parenchymal organ within the past 3 months Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent Subjects who currently smoke (intake nicotine or nicotinecontaining products) or have given up smoking for less than 6 months before the first administration of study drug Subjects who are carriers of the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody or who are Human Immunodeficiency Virus (HIV) antibody positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>